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ABSTRACT
Background: Commentaries on the adequacy of insurance coverage for prescription drugs available to Canadians 
have emphasized differences in the coverage provided by different provincial governments. Less is known about the 
actual financial burden of prescription drug spending and how this burden varies by province of residence, affluence 
and source of primary drug coverage. 
Methods: We used data from a nationally representative household expenditure survey to analyze the financial burden 
of prescription drugs. We focused on the drug budget share (defined as the share of the household budget spent on 
prescription drugs), considering how it varied by province, total household budget and likely primary source of drug 
insurance coverage (i.e., provincial government plan for senior citizens, social assistance plan or private coverage). 
We examined both “typical” households (at the median of the distribution of the drug budget share) and households 
with relatively large shares (in the top 5%). Finally, we estimated the percentage of households with catastrophic drug 
expenditures (defined as a drug budget share of 10% or more) and the average catastrophic drug expenditures.
Results: Senior, social assistance and general population households accounted for 21.1%, 8.9% and 69.9% of the 
sample of 14 430 respondents to the 2006 Survey of Household Spending, respectively. The median drug budget 
share in Canada was 1.1% for senior households (range 0.4% [Ontario] to 3.6% [Saskatchewan]) and 0.1% for both 
social assistance households and general population households, with little appreciable variation across provinces for 
these latter 2 categories. The 95th percentile drug budget share in Canada was 7.4% for senior households (range 3.5% 
[Ontario] to 12.7% [Saskatchewan]), 5.4% for social assistance households (range 2.3% [British Columbia] to 13.0% 
[Prince Edward Island]) and 2.6% for general population households (range 2.1% [Ontario] to 5.4% [Prince Edward 
Island]). The interprovincial range of the 95th percentile drug budget share was 10.7 percentage points for social 
assistance households, 9.2 percentage points for senior households and 3.3 percentage points for general population 
households.
Interpretation: For most households, the financial burden of prescription drug expenditures appeared to be relatively 
small, with little interprovincial variation. However, a small number of households incurred catastrophic drug costs. 
These households were concentrated in the groups that traditionally benefit from provincial government drug plans. 
It is likely that some households did not purchase needed prescription drugs because of the expense, so our estimates 
of the financial burden of catastrophic prescription drug expenditures therefore represent a lower bound.
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roposals for a national, publicly financed drug 
plan continue to be debated in Canada. Propon-
ents point to the large number of studies identi-
fying differences in provincial government drug cover-
age available to individuals depending on province of 
residence, age, income and types of drugs needed. For 
instance, a recent contribution to this burgeoning lit-
erature identified a 63-fold interprovincial variation in 
what an elderly person would be expected to pay out of 
pocket (OOP) for a medication regimen of antihyperten-
sive drugs.1 Other studies simulating OOP drug costs 
have  focused  on  differences  in  coverage  available  to 
individuals with different ages and incomes,2–5 individ-
uals with catastrophic drug expenditures6,7 and individ-
uals who lack coverage for specific drugs, such as those 
used in cancer treatment.8–13
Simulation studies provide useful information about 
differences in the design of drug plans. However, they do 
not necessarily reflect what individuals actually pay OOP 
for prescription drugs. Yet information on the financial 
burden  of  prescription  drugs  is  important  for  policy- 
making in this area. For several reasons, the reported 
simulation studies have not necessarily provided policy-
relevant information on the actual financial burden posed 
by prescription drugs. First, simulation studies ignore the 
fact that beneficiaries of the provincial government plans 
may have other sources of drug coverage, including Vet-
erans Affairs benefits and spousal coverage. Simulation 
studies also tend to focus on coverage of so-called “general 
benefit” drugs, which are reimbursed without restriction. 
Formulary restrictions imposed on the reimbursement of 
“limited-use” drugs—which tend to be newer and more 
costly—are typically not taken into account. 
Second, the complexity of design of provincial drug 
plans can easily lead to errors that will materially af-
fect  the  results  of  a  simulation  study.  For  example, 
O’Sullivan14 questioned the assertion of Demers and col-
leagues1 that a senior resident of New Brunswick with 
a household income of $45,000 is required to pay an 
annual premium of $60. O’Sullivan14 indicates that the 
monthly premium is $89. After correction of this error, 
OOP costs (depicted in Figure 2 of the study by Demers 
and colleagues) would increase from $60 to $1,068 (12 × 
$89). In addition, we note that the maximum OOP costs 
for Quebec seniors who receive 93% or less of their Guar-
anteed  Income  Supplement  was  $47.51  per  month  in 
2006, not $73.42 as reported by Demers and colleagues. 
Correcting for both these errors substantively alters the 
distribution of the interprovincial variations reported 
by Demers and colleagues, conceivably changing their 
conclusions. 
Third, simulation studies tend to ignore household-
level  resources  in  measurement  of  financial  burden. 
However, welfare economics emphasizes that the house-
hold  is  the  relevant  decision-making  unit,  given  that 
household members typically pool resources and make 
important  expenditure  decisions  collectively.15  Fourth, 
simulation studies typically do not recognize that indi-
viduals adapt to the design of a drug plan in ways that 
lower their expenditures. For instance, individuals con-
fronted with a fixed fee per prescription can economize 
by  increasing  the  number  of  tablets  per  prescription. 
Finally, such studies simulate the OOP costs for several 
types of individuals (distinguished by age, types of drugs 
used and income) but fail to consider the OOP costs for 
the entire distribution of individuals.
One  way  to  mitigate  these  limitations—and  provide 
additional policy-relevant information—is to use nation-
ally representative household-level survey data on house-
hold resources and expenditures on prescription drugs. 
In the study reported here, we used such data to estimate 
the share of the household budget allocated to prescrip-
tion drugs and to assess how the drug budget share var-
ied by province of residence and level of affluence for 3 
different types of households differing in their primary 
source of coverage: senior citizens and recipients of social 
assistance (who are usually beneficiaries of the provincial 
government drug plan) and all others (who tend to rely on 
private plans). These survey data allowed us to gain new 
insights into the distribution of drug budget share. In par-
ticular, we focused on households at the median and at the 
95th percentile of the distribution of drug budget share. 
We  also  estimated  the  proportion  of  households  that 
spent 10% or more of their budget on prescription drugs.
Methods
Data sources. Data for this cross-sectional study were 
obtained  from  Statistics  Canada’s  2006  Survey  of 
Household Spending (SHS). The SHS surveyed a strati-
fied, multistage sample of residential households in the 
10 provinces, based on the sampling frame of the Can-
adian Labour Force Survey. 
Face-to-face interviews with respondents were con-
ducted  between  January  and  March  2007  to  collect 
information  about  household  expenditures  (includ-
ing prescription drug expenditures not reimbursed by 
drug insurance plans) and income for the calendar year 
2006.16 Extensive efforts were made to ensure the qual-
ity of the responses.16 Respondents were asked to consult 
bills and receipts to confirm reported expenditure infor-
mation, and household income was carefully reconciled 
with household expenditures and savings.16
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as the ratio of the household’s out-of-pocket prescription 
drug expenditures to its total budget. Following the same 
method as Alan and colleagues,17 we defined the total 
household budget as its outlays on all goods and servi-
ces,  excluding  expenditures  on  costly  durables  (cars, 
trucks and recreational vehicles). Because a household’s 
annual budget reflects the effects of saving and borrow-
ing, it better reflects the household’s permanent income, 
including prior savings and anticipated future income, 
and is less variable than its current income.
We defined the likely source of primary drug coverage 
according to 3 household types: senior, social assistance 
and general population. We defined senior households 
as  households  for  which  the  reference  person  was  65 
years of age or older, where the reference person is de-
fined as the household member most responsible for the 
household’s financial affairs, including paying rent and 
utility  bills.  We  defined  social  assistance  households 
as non-senior households in which 50% or more of the 
household income came from government transfers such 
as unemployment insurance and welfare benefits. The 
remaining households were defined as general popula-
tion households (i.e., non-senior households in which the 
majority of income came from nongovernment sources).
The  comprehensiveness  of  a  household’s  primary 
source  of  drug  coverage  varies  by  province.  All  prov-
incial  governments  provide  drug  subsidies  to  senior 
citizens and social assistance recipients. General popu-
lation households typically rely on private drug plans. 
In some cases in which a general population household 
lacks comprehensive drug coverage from other sources, 
the provincial government provides drug coverage. How-
ever, provincial coverage for general population house-
holds tends to be the least comprehensive, as provincial 
plans typically cover only those drug expenditures in ex-
cess of a deductible, which is determined by household 
size and income.
The drug budget share bears more than a simple math-
ematical relation to the size of the household’s budget. 
Although a direct mathematical relation does exist be-
tween the drug budget share and the size of the house-
hold’s budget (since drug budget share is defined as the 
ratio of the household’s out-of-pocket prescription drug 
expenditures to the total household budget), an indirect 
relationship between drug budget share and budget size 
is also likely, since the amount that a household chooses 
to spend on prescription drugs may be determined, in 
part, by the overall size of its budget. For example, rela-
tive to a household with a small total budget, a household 
with a large total budget may choose to spend more on 
prescription drugs because it can spend a smaller share 
of the budget on necessities such as housing, food and 
clothing without forgoing basic needs.
Statistical methods. We took 3 approaches to analyzing 
the data. First, we estimated the median and 95th per-
centile for household budget, out-of-pocket prescription 
drug expenditures and drug budget share, by province of 
residence and household type.
Second, for each combination of household type and 
province, we estimated the relation between the house-
hold’s drug budget share and its total budget. This al-
lowed us to assess the interprovincial variation in the 
financial  burden  for  drugs  faced  by  households  with 
similar  levels  of  affluence.  The  relation  between  drug 
budget share and budget, known in economics as an En-
gle curve,17 is also of interest in its own right. The slope 
of the curve reflects how spending on prescription drugs 
not covered by a drug plan changes with household af-
fluence and thus yields some insights into the distribu-
tional effects of current drug insurance arrangements. 
We  estimated  the  Engle  curve  for  households  at  2 
specific points in the distribution of drug budget shares. 
In particular, we focused on households with the median 
(i.e., 50th percentile) drug budget share and the 95th 
percentile drug budget share. The median drug budget 
share is the point at which half of households face a lower 
burden and the other half face a higher burden. The 95th 
percentile drug budget share reflects the financial bur-
den of households with a large drug budget share (such 
that only 5% of households face a higher burden) and 
tends to correspond to households without comprehen-
sive drug coverage.
To estimate the Engle curve for the median and 95th 
percentile drug budget share, we used a nonparametric 
kernel conditional quantile estimator.18 This estimation 
approach has much to recommend it.  Perhaps its great-
est advantage, however, is that this approach does not 
require one to assume a particular algebraic form of the 
Engle curve, as one does for linear regression and other 
commonly used techniques.
We generated the Engle curves using the predicted 
values  from  the  kernel  conditional  quantile  estimator 
over an assumed household budget range of $0 to $60 
000 ($0 to $100 000 for general population households). 
A simple way to interpret different points along an Engle 
curve is to recall that a 1% budget share represents $200 
of a $20 000 household budget and $400 of a $40 000 
household budget.
Finally,  we  examined  households  with  catastroph-
ic  out-of-pocket  drug  expenditures,  defined  as  a  drug 
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ed the proportion of households with such catastrophic 
drug expenditures and calculated their average out-of-
pocket drug expenditures.
To account for oversampling and undersampling of 
different  geographic  regions  and  demographic  groups 
within the SHS, we used the survey sampling weights 
provided by Statistics Canada when generating popula-
tion estimates.16
Results
The 2006 SHS had a response rate of 71.6%, and a sam-
ple size of 14 430 households. This sample is intended 
to be representative of 12.6 million Canadian commun-
ity dwelling households. We classified 3048 households 
(21.1%) as senior households, 1291 (8.9%) as social assist-
ance households and 10 091 (69.9%) as general popula-
tion households. 
Descriptive  statistics.  The  median  household  budget 
in Canada for 2006 was $23 337 for senior households 
(range $18 776 [Newfoundland and Labrador] to $24 591 
[British Columbia]), $19 658 for social assistance house-
holds (range $15 731 [Manitoba] to $23 893 [Alberta]) 
and $44 652 for general population households (range 
$37 378 [New Brunswick] to $51 906 [Alberta]) (Table 1). 
The median household out-of-pocket prescription drug 
expenditure in Canada was $275 for senior households 
(range $120 [Ontario] to $684 [Saskatchewan]), $8 for 
social assistance households (range $0 [Newfoundland 
and Labrador, Ontario, Manitoba, British Columbia] to 
$100 [Prince Edward Island]) and $50 for general popu-
lation households (range $40 [Ontario] to $160 [Prince 
Edward Island]) (Table 1). The median drug budget share 
in Canada was 1.1% for senior households (range 0.4% 
[Ontario] to 3.6% [Saskatchewan]) and was considerably 
lower for social assistance households (0.1%) and gener-
al population households (0.1%), with little appreciable 
variation across provinces (Table 1).
The  95th  percentile  household  budget  in  Canada 
was  $59 651  for  senior  households  (range  $39 234 
[Newfoundland  and  Labrador]  to  $69  131  [Ontario]), 
$58 001 for social assistance households (range $38 494 
[Prince Edward Island] to $77 774 [British Columbia]) 
and $99 083 for general population households (range 
$71 647 [New Brunswick] to $110 665 [Alberta]) (Table 
1). The 95th percentile household out-of-pocket prescrip-
tion drug expenditure in Canada was $2000 for senior 
households (range $1000 [Ontario] to $2900 [Saskatch-
ewan]), $1200 for social  assistance  households  (range 
$900 [Manitoba] to $4284 [Prince Edward Island]) and 
$1160 for general population households (range $1000 
[Alberta, Quebec] to $1600 [Newfoundland and Labra-
dor]) (Table 1). The 95th percentile drug budget share 
in Canada was 7.4% for senior households (range 3.5% 
[Ontario] to 12.7% [Saskatchewan]), 5.4% for social as-
sistance households (range 2.3% [British Columbia] to 
13.0%  [Prince  Edward  Island])  and  2.6%  for  general 
population  households  (range  2.1%  [Ontario]  to  5.4% 
[Prince Edward Island]) (Table 1). The interprovincial 
range for the 95th percentile drug budget share was 10.7 
percentage points for social assistance households, 9.2 
for  senior  households  and  3.3  for  general  population 
households. These ranges were noticeably wider than the 
corresponding  interprovincial  ranges  in  median  drug 
budget share for the 3 household types.
Engle curves. For the sake of clarity, we present the En-
gle curves for only the most populous provinces (Quebec, 
Ontario and British Columbia) and the province yielding 
the maximum value of drug budget share. For the sake 
of brevity, we have not presented the Engle curves at the 
median drug budget share for the social assistance and 
general population households, as there was little inter-
provincial  variation  in  these  categories,  and  the  drug 
budget shares were small (< 0.5%).
Among senior households with a budget of $10 000, 
the median drug budget share ranged from under 1% 
(Ontario) to over 3% (Saskatchewan) (Figure 1, showing 
Engle  curves  for  Quebec,  Ontario,  Saskatchewan  and 
British Columbia). As household budget increased, the 
Engle curves for Ontario and British Columbia remained 
fairly flat, whereas the Engle curves for Quebec and Sas-
katchewan sloped downward. At a household budget of 
$60 000,  the  interprovincial  variation  in  drug  budget 
share had decreased, and the values ranged from less 
than 1% (Ontario) to about 1.5% (Saskatchewan).
Among senior households with a budget of $10 000, 
the 95th percentile drug budget share ranged from 6% 
(Ontario) to more than 12% (Saskatchewan) (Figure 2, 
showing  Engle  curves  for  Quebec,  Ontario,  Saskatch-
ewan and British Columbia). As household budget in-
creased, the Engle curves for British Columbia, Quebec 
and Ontario decreased slightly, whereas the Engle curve 
for Saskatchewan remained fairly flat. At a household 
budget of $60 000, the interprovincial variation in drug 
budget share had increased, and the values ranged from 
4% (British Columbia) to over 12% (Saskatchewan).
Among social assistance households with a budget of 
$10 000, the 95th percentile drug budget share ranged from 
just under 6% (Quebec) to about 9% (Prince Edward Island) 
(Figure 3, showing Engle curves for Prince Edward Island, 
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for all provinces tended to increase with household budget 
up to $40 000, after which the curves tended to decrease 
again. At a household budget of $60 000, the interprovin-
cial variation in drug budget share had declined, and the 
values ranged from 3% (Ontario, Quebec) to 4% (Prince Ed-
ward Island). Among general population households with a 
budget of $10 000, the 95th percentile drug budget share 
ranged from about 3.5% (Ontario) to about 4.5% (New-
foundland  and  Labrador)  (Figure  4,  showing  curves  for 
Newfoundland and Labrador, Quebec, Ontario and British 
Columbia). The Engle curves for all provinces decreased 
as household budget increased. At a household budget of 
$60 000, the interprovincial variation in drug budget share 
had declined, and the values ranged from about 2.5% (On-
tario) to 3% (Newfoundland and Labrador). At a household 
budget of $100 000, the interprovincial variation in drug 
budget share had declined even further.
Catastrophic  drug  expenditures.  There  was  marked 
interprovincial  variation  in  the  fraction  of  senior  and 
social assistance households that incurred catastrophic 
drug expenses (i.e., at least 10% of the household budget 
on out-of-pocket prescription drug expenses) (Table 2).
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Table 1:  Household budget, prescription drug budget expenditure and share, by household type and province, as determined 
in the 2006 Survey of Household Spending (14 430 respondents)
Household type* and province n Median value 95th percentile
Household 
budget, $
Drug 
expenditure, $
Drug budget 
share, %
Household 
budget, $
Drug 
expenditure, $
Drug budget 
share, %
Senior (age ≥ 65 yr)
Newfoundland and Labrador 280 18 776 252 1.3 39 234 2 400 10.8
Prince Edward Island 141 22 383 500 2.0 50 114 2 200 11.8
Nova Scotia 315 22 528 300 1.3 48 935 1 400 6.5
New Brunswick 291 20 340 300 1.4 45 520 2 000 8.4
Quebec 371 23 147 560 2.4 55 793 1 920 7.4
Ontario 425 23 592 120 0.4 69 131 1 000 3.5
Manitoba 318 20 281 500 2.6 48 582 2 500 11.0
Saskatchewan 340 19 993 684 3.6 43 836 2 900 12.7
Alberta 205 24 458 300 1.2 59 373 2 000 8.2
British Columbia 362 24 591 300 1.2 65 325 2 500 9.1
Total 3 048 23 337 275 1.1 59 651 2 000 7.4
Social assistance (age < 65 yr)
Newfoundland and Labrador 226 18 591 0 0.0 45 096 2 400 11.0
Prince Edward Island 65 23 370 100 0.5 38 494 4 284 13.0
Nova Scotia 168 16 826 30 0.2 47 685 1 800 7.8
New Brunswick 151 20 278 80 0.3 52 155 2 400 10.2
Quebec 182 18 608 27 0.2 54 221 1 044 4.5
Ontario 161 19 855 0 0.0 60 022 1 200 5.8
Manitoba 116 15 731 0 0.0 41 332    900 5.0
Saskatchewan 81 20 564 10 0.1 56 232 2,000 7.8
Alberta 53 23 893 45 0.2 70 939 1 440 3.0
British Columbia 88 22 439 0 0.0 77 774 1 000 2.3
Total 1 291 19 658 8 0.1 58 001 1 200 5.4
General population (age < 65 yr)
Newfoundland and Labrador 804 40 360 100 0.2 81 029 1 600 4.3
Prince Edward Island 397 40 167 160 0.3 78 079 1 500 5.4
Nova Scotia 910 39 763 74 0.2 83 049 1 200 3.0
New Brunswick 858 37 378 81 0.2 71 647 1 300 4.3
Quebec 1 315 38 496 80 0.2 80 217 1 000 2.8
Ontario 1 533 48 630 40 0.1 108 223 1 200 2.1
Manitoba 1 020 39 688 50 0.1 78 483 1 300 3.8
Saskatchewan 997 39 487 50 0.1 79 905 1 440 3.6
Alberta 1 098 51 906 50 0.1 110 665 1 000 2.2
British Columbia 1 159 47 852 60 0.2 110 329 1 200 2.4
Total 10 091 44 652 50 0.1 99 083 1 160 2.6
* Household type was de￿  ned on the basis of the reference person, the household member most responsible for the household’s ￿  nancial a￿  airs, including paying rent 
   and utility bills.The proportion of senior households with catastroph-
ic drug expenditures was 2.5% for all of Canada (range 
0.5%  [Ontario]  to  10.4%  [Saskatchewan]),  with  mean 
out-of-pocket catastrophic drug expenditures of $3609 
(range $2310 [Alberta] to $4553 [British Columbia]). In 
most provinces, less than 3% of social assistance house-
holds had catastrophic drug expenses. Overall, the pro-
portion of social assistance households with catastrophic 
drug expenditures was 1.1% (range 0% [British Colum-
bia] to 15.9% [Prince Edward Island), with mean out-of-
pocket catastrophic drug expenditures of $3634 (range 
$0 [British Columbia] to $6559 [Ontario]). Finally, the 
proportion of general population households with cat-
astrophic drug expenditures was 0.3% for all of Canada 
(range 0.1% [British Columbia] to 1.6% [Prince Edward 
Island]), and the mean out-of-pocket catastrophic drug 
expenditures for these households was $5145 for all of 
Canada (range $3602 [Prince Edward Island] to $7800 
[Alberta]).
Interpretation
In  this  study,  we  found  that  the  financial  burden  of 
out-of-pocket  prescription  drug  expenditures  for  the 
typical  household  was  relatively  small,  with  little 
interprovincial variation. The maximum median drug 
budget share was 3.6% (for senior households in Sas-
katchewan). Similarly, general population households 
experiencing a large financial burden had a maximum 
drug budget share of 5.4% (Prince Edward Island). In 
short, coverage for prescription drugs appeared to be 
adequate for the majority of Canadian households, al-
though recent simulation studies have suggested that 
the opposite is true.
Nonetheless,  some  Canadian  households  were  pur-
chasing  expensive  pharmaceutical  therapies  without 
the benefit of comprehensive drug insurance. Somewhat 
surprisingly, such households were concentrated in the 
groups that traditionally benefit from provincial govern-
ment drug plans. In particular, 2.5% of senior house-
holds and 1.1% of social assistance households in Canada 
faced catastrophic drug expenditure in 2006, whereas 
only 0.3% of general population households faced cat-
astrophic expenses. Like previously reported simulation 
studies, we found substantial interprovincial variation 
in  the  prevalence  of  catastrophic  costs  among  senior 
and social assistance households. Because of the small 
number of households in the SHS that incurred catas-
trophic drug expenses, these estimates should be inter-
preted with caution. However, the estimates do reflect 
differences in provincial drug plan coverage and hence 
appear  plausible.  In  particular,  rates  of  catastrophic 
drug  expenditures  for  senior  households  were  higher 
in provinces with less generous coverage. For instance, 
less than 1% of senior households in Ontario (a province 
with generous coverage for seniors) incurred catastroph-
ic costs, whereas over 10% of senior households in Sas-
katchewan (where coverage in 2006 was less generous 
for senior citizens) incurred catastrophic costs. Notably, 
Saskatchewan has recently increased drug coverage for 
seniors, as described by the National Prescription Drug 
Utilization Information System (https://secure.cihi.ca/
estore/productSeries.htm?pc=PCC294).  In  the  general 
population, catastrophic costs were concentrated among 
less affluent households. This finding could be of prac-
tical importance to policy-makers if they consider tar-
geting the benefits of a national pharmacare program at 
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Table 2:  Proportion of households spending at least 10% of their budget on prescription drugs, and mean 
prescription drug expenditures within this group, by household type* and province, as determined in the 2006 
Survey of Household Spending (14 430 respondents)
Province Senior (age ≥ 65 yr)
Social assistance
 (age < 65 yr)
General population
 (age < 65 yr)
% spending ≥ 
10% on drugs
Mean 
expenditures, $
% spending ≥ 
10% on drugs
Mean 
expenditures, $
% spending ≥ 
10% on drugs
Mean 
expenditures, $
Newfoundland and Labrador 6.2 2734 5.7 2749 1.3 5319
Prince Edward Island 8.6 3022 15.9 3818 1.6 3602
Nova Scotia 2.0 3298 2.8 2720 1.0 5080
New Brunswick 4.0 2521 5.4 3091 0.5 4727
Quebec 2.5 3774 0.7 2976 0.4 5258
Ontario 0.5 3883 0.5 6559 0.2 5520
Manitoba 6.1 3697 1.1 2200 0.9 4471
Saskatchewan 10.4 3055 1.2 2200 0.8 4037
Alberta 2.3 2310 2.1 3300 0.2 7800
British Columbia 4.0 4553 0.0 0 0.1 4018
Total 2.5 3609 1.1 3634 0.3 5145
* Household type was de￿  ned on the basis of the reference person, the household member most responsible for the household’s ￿  nancial a￿  airs, 
   including paying rent and utility bills.households that incur a large financial burden for out-of-
pocket prescription drug expenditures.
It is unclear how a household’s total budget (i.e., af-
fluence) affects its drug budget share. If drug purchase 
decisions  do  not  depend  on  affluence,  then  it  follows 
mathematically that the drug budget share will decline 
as  the  total  budget  increases.  However,  more  affluent 
households are more likely than less affluent households 
to be able to afford drugs not covered by insurance. Such 
uninsured  drugs  might  include  drugs  used  in  fertility 
treatments and biologic drugs used in cancer treatment, 
as well as various lifestyle drugs, such as those used to 
treat hair loss or erectile dysfunction. Hence, it is possible 
the drug budget share may actually increase with total 
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Figure 1: Engle curves for  
median drug budget share  
for senior households, for  
the most populous provinces  
(British Columbia, Ontario  
and Quebec) and the province 
with the maximum value  
(Saskatchewan)
Figure 2: Engle curves for  
the 95th percentile drug  
budget share for senior  
households, for the most 
populous provinces (British 
Columbia, Ontario and  
Quebec) and the province 
with the maximum value  
(Saskatchewan)
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the relation between drug budget share and household 
budget reflects the effect of affluence on the incidence 
of disease and, for people with a diagnosed disease, the 
awareness of households of various therapeutic options.
Although  the  use  of  representative  national  survey 
data provides a reasonable picture of the financial burden 
faced by households, this study had a few important lim-
itations. First, our classification of households as senior, 
social assistance or general population households did 
not completely control for all types of insurance coverage 
that each household might have. This limitation might 
have  biased  our  results,  as  out-of-pocket  prescription 
drug expenditures would be lower for households with 
Open Medicine 2011;5(1):e8
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Figure 3: Engle curves for the 
95th percentile drug budget 
share for social assistance 
households, for the most 
populous provinces (British 
Columbia, Ontario and  
Quebec) and the province 
with the maximum value 
(Prince Edward Island)
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Figure 4: Engle curves for the 
95th percentile drug budget 
share for general population 
households, for the most 
populous provinces (British 
Columbia, Ontario and  
Quebec) and the province 
with the maximum value 
(Newfoundland and Labrador)multiple types of insurance coverage. Second, although 
we controlled for broad types of households (i.e., senior, 
social assistance and general population households), we 
cannot control for the exact age or health status of all 
household members. This limitation might have biased 
our results because we could not control for potential 
factors related to increased consumption of prescription 
drugs. However, such potential bias is likely of little con-
cern, as we focused primarily on interprovincial varia-
tion in the financial burden of prescription drugs, and 
age  and  health  status  were  presumably  not  meaning-
fully different across the 10 provinces. Finally, the drug 
expenditure  data  did  not  reflect  “unmet  needs.”  That 
is, some prescription drugs are simply unaffordable for 
some households and hence are not purchased. Indeed, 
three-quarters of newer cancer drugs taken at home cost 
over $20 000 annually.19 Our estimates of the financial 
burden of catastrophic prescription drug expenditures 
therefore represent a lower bound. 
We  concur  with  the  First  Ministers  of  Health  that 
some policy intervention is needed to improve the wel-
fare  of  households  who  face  high  drug  costs  without 
comprehensive coverage.2
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